vedolizumab (Entyvio) (Last Updated: Apr 30, 2021)
Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name
Manufacturer
Submission Type
Indications
Brand Name:
Entyvio
Manufacturer:
Takeda Canada Inc.
Submission Type:
Initial
Indications:
For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to immunomodulators or a TNFα antagonist; or have had an inadequate response, intolerance, or demonstrated dependence on corticosteroids.